Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Advanced renal cell carcinoma Age: Adult |
Dose: Intravenous – 3 mg/kg Frequency: every 2 weeks Note: Given via infusion over 60 minutes. Continued until disease progression or unacceptable toxicity. |
|
Indication: Locally advanced non-small cell lung carcinoma Age: Adult |
Dose: Intravenous – 3 mg/kg Frequency: every 2 weeks Note: Given via infusion over 60 minutes. Continued until disease progression or unacceptable toxicity. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic colorectal cancer Age: greater than 12 years |
Dose: Intravenous infusion – 240 mg Frequency: every 2 weeks Note: given via infusion over 60 minutes. Continued until disease progression or unacceptable toxicity. |
|
Indication: Metastatic colorectal cancer Age: greater than 12 years |
Dose: Intravenous infusion – 480 mg Frequency: every 4 weeks Note: given via infusion over 60 minutes. Continued until disease progression or unacceptable toxicity. |
Administration
- Given as IV infusion over 30-60 minutes
- Must be administered by healthcare professionals
Side Effect
- Melanoma
- Increased AST (28%)
- Hyponatremia (25%)
- Increased alkaline phosphatase (22%)
- Rash (21%)
- Pruritus (19%)
- Cough (17%)
- Increased ALT (16%)
- Hyperkalemia (15%)
- URTI (11%)
- NSCLC
- Fatigue (50%)
- Lymphopenia (47%)
- Dyspnea
- hyponatremia (38%)
- Musculoskeletal pain (36%)
- Cough (32%)
- Nausea (29%)
- Increases creatinine (22%)
- Hypercalcemia
- hypokalemia
- hypomagnesemia (20%)
- Vomiting
- asthenia (19%)
- Hypocalcemia
- hyperkalemia
- diarrhea (18%)
- Edema
- pyrexia (17%)
- Abdominal pain
- rash
- increased AST (16%)
- Increased alkaline phosphatase
- thrombocytopenia (14%)
- Chest pain
- arthralgia
- decreased appetite and weight (13%)
- Increased ALT (12%)
- Melanoma
- Peripheral edema (10%)
- NSCLC
- Pneumonia (10%)
- Pain (10%)
- Melanoma
- Hyponatremia (5%)
- Increased AST (2.4%)
- Increased alkaline phosphatase (2.4%)
- Hyperkalemia (2%)
- Increased ALT (1.6%)
- NSCLC
- Dyspnea (9%)
- Fatigue (7%)
- Musculoskeletal pain (6%)
- Pneumonia (5%)
- Decreased appetite (2.6%)
- Pain (2.6%)
- Nausea (1.7%)
- Abdominal pain (1.7%)
- Asthenia (1.7%)
- Edema (1.7%)
- Cough (1.7%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Immunosuppressants (Cyclosporine, Tacrolimus, Mycophenolate, Azathioprine)
|
Potentially Fatal: Decreased therapeutic effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store under refrigeration at 2°C to 8°C. Protect from light by storing in the original package until time of use. Do not freeze or shake.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.